Visual Acuity Following Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma

Research Article

Austin J Clin Ophthalmol. 2018; 5(1): 1088.

Visual Acuity Following Transscleral Cyclophotocoagulation as Primary Surgical Treatment for Primary Open Angle Glaucoma

Lei-Ai Lim¹*, Inderraj Hanspal² and Daniel Byles³

¹Moorfields Eye Hospital Foundation NHS Trust,UK

²West Suffolk NHS Trust,UK

³Royal Devon and Exeter Foundation NHS Trust, UK

*Corresponding author: Lei-Ai Lim, Taunton and Somerset Foundation NHS Trust, Musgrove Park Hospital, Taunton, Somerset TA1 5DA, UK

Received: February 13, 2018; Accepted: March 12, 2018; Published: March 22, 2018

Abstract

Purpose: The aim of this study was to report the effect of TSCP as primary surgical treatment for primary open angle glaucoma (POAG) on eyes with good pre-treatment visual acuity.

Methods: Retrospective case notes review of patients who underwent TSCP for POAG between January 2002 and December 2006 at the West of England Eye Unit. Only patients with a pre-treatment Snellen visual acuity of 6/12 or better were included. 1 year follow up data was analysed.

Results: 27 of 43 patients underwent TSCP for POAG from January 2002 and December 2006 had visual acuity of 6/12 or better prior to TSCP. 15/27 (56%) maintained their visual acuity within 1 line at 1 year. 12/27 (44%) lost more than one Snellen line of acuity. The mean pre-treatment IOP was 22mmHg (SE 1.43). Following treatment the IOP at 1, 6 and 12 months were: 14mmHg (SE 1.49), 13mmHg (SE 0.94) and 13mmHg (SE 0.90) respectively (P<0.001 one-way repeated measures ANOVA).

Comparing the group maintaining vision with the group losing vision, there was no significant difference between the pre-treatment IOP (0.37 unpaired t-test) or the IOP reduction (p=0.18 unpaired t-test). The pre-treatment visual fields showed mean deviation values of -12.93 (SE 1.82) in the group that maintained visual acuity and -19.17 (SE 1.96) in the group that lost visual acuity (P=0.018 unpaired t-test).

Conclusions: TSCP for patients with POAG and good pre-treatment acuities carries a significant risk of visual deterioration, which can sometimes be severe. TSCP should be used with caution in this group of patients with advanced visual field loss.

Keywords: Primary Open Angle Glaucoma; Transscleral cyclophotocoagulation; Pretreatment

Introduction

Transscleral cyclophotocoagulation (TSCP) has an established role in the management of refractory glaucoma [1-9]. There are fewer publications with regards to its use as primary surgical treatment for primary open angle glaucoma (POAG) in patients with good pretreatment visual acuity [10-13]. In particular, the effect of TSCP on visual acuity in patients with POAG and good pre-treatment acuity is poorly documented in the literature. This study focussed on the effect of TSCP on patients with good pretreatment visual acuity for medically uncontrolled POAG.

Methods

A retrospective case note review was conducted of all patients who underwent TSCP for POAG between January 2002 and December 2006 at the West of England Eye Unit. All patients were treated with TSCP by a single surgeon, using the same treatment protocol. Data collected included age, sex, Snellen visual acuity and intraocular pressure (IOP measured by Goldman applanation tonometry) pre- treatment, at 1 month, 6 months and 12 months following TSCP. The number of anti-glaucoma medications pre and post TSCP and pre-treatment mean deviation as measured by the Humphrey field analyser using the SITA 24-2 protocol were also recorded.

Only patients with pre-treatment best corrected Snellen acuity of 6/12 or better were included in the final analysis.

The indication of TSCP was IOP uncontrolled with maximum tolerated medical treatment, unsuitability (either due to age or complex medical conditions) or refusal of filtration surgery.

All TSCP were performed following subtenon’s local anaesthesia as day case procedures using the OcuLight Slx semiconductor diode 810nm laser with disposable contact G probe. All patients had informed consent following discussion of treatment options and explanation of the procedure. Transillumination was performed to determine the anterior segment morphology prior to delivery in each case of 32 shots (8 per quadrant over 360 degrees) with default energy setting of 3W and 1.5sec. If a “pop” sound was audible during treatment, the power was decreased by 200mW until no further “pops” was heard. All patients received topical Betnesol ointment immediately following treatment and were instructed to instil Guttae Maxitrol for 4-6 weeks post treatment along with pre-treatment antiglaucoma medication. None of the patients were on oral Acetazolamide prior to TSCP. Retreatment settings were unchanged.

All findings were reported as means with standard error (SE) of the mean. All p values were calculated using unpaired two-way t-test unless stated otherwise.

Results

A total of 43 patients with POAG had cyclodiode laser between January 2002 and December 2006. 27 patients with pre-treatment Snellen visual acuity of 6/12 or better were included in the final analysis. The 16 patients who were excluded all had visual acuities of 6/60 or worse.

The mean age was 81 years. There were 13 (48%) male and 14 (52%) females.

At one year follow up, 15 of the 27 (56%) patients maintained their Snellen visual acuity within 1 line of their pretreatment visual acuity. 12 out of the 27 patients (44%) had reduction of visual acuity of greater than one line on the Snellen chart. Of the latter, 7 patients (26%) lost 2 lines, 3 patients (11%) lost 3 lines and 2 patients (7%) went from 6/6 to 2/60 and HM respectively (Figure1). The reason for loss of vision was progression of glaucomatous optic neuropathy (GON).

The mean pre-treatment IOP was 22mmHg (SE 4.76). The mean post treatment IOPs were 14mmHg (SE 7.69) at 1 month, 13mmHg (SE 4.79) at 6 months and 13mmHg (SE 3.94) at 1 year. The mean reduction in IOP with TSCP did not differ in the group that maintained visual acuity compared to the group that lost vision. In the group that maintained visual acuity, the mean pre-treatment IOP was 22mmHg (SE 5.16) and the mean post-treatment IOPs were 14mmHg (SE 5.46) at 1 month, 13mmHg (SE 3.04) at 6 months and 14mmHg (SE 3.71) at 1 year. In the group with significant reduction in visual acuity, the mean pre-treatment IOP was 21mmHg (SE 4.25) and the mean post-treatment IOPs were 14mmHg (SE 10.09) at 1 month, 12mmHg (SE 6.63) at 6 months and 12mmHg (SE 3.94) at 1 year (Figure 2). The percentage IOP reduction for the group that maintained visual acuity was 31.8% and that for the group that lost visual acuity was 42.1%.